Yoshinori Taniguchi

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 214 citations

Medicine, Clinical Sciences, Pharmacotherapy +10

Sestrin-2 and BNIP3 regulate autophagy and mitophagy in renal tubular cells in acute kidney injury

Masayuki Ishihara, Madoka Urushido, Kazu Hamada et al. · American Journal of Physiology-Renal Physiology · 2013 · 196 citations

Life Sciences, Cell Biology, Pathobiology +17

Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients

Shinji Sato, Kenichi Masui, Naoshi Nishina et al. · Lara D. Veeken · 2018 · 159 citations · Full text

Medicine, Immunology, Internal Medicine +17

Exploration of genes showing intramuscular fat deposition‐associated expression changes in musculus longissimus muscle

Yusuke Sasaki, Koutatsu Nagai, Y. Nagata et al. · Animal Genetics · 2005 · 104 citations

Life Sciences, Animal Sciences, Molecular Biology +17